Impact of Oral Magnesium on Neuropathic Pain

Phase 4

Completed

• Conditions: Patient With Neuropathic Pain

• Registration Number: NCT01121653
• Lead Sponsor: University Hospital, Clermont-Ferrand

Brief Summary

Use lay language.

The aim of this study is to evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.

Detailed Description

Protocol description

Visit D0

* patient inclusion after informed signed consent

* clinical exam

* blood sampling (magnesium dosage)

* questionnaires (neuropathic pain and quality of life)

* daily self-evaluation on neuropathic pain scale (Week0 to Week5)

D8 : first intake of study drug (magnesium or placebo)

Visit Week5:

* questionnaires (neuropathic pain and quality of life)

* blood sampling (magnesium dosage)

* clinical exam

Study Timeline

• Study Start: 2006-03
• Primary Completion: 2008-01
• Study Completion: 2008-06
• Status Verified: 2010-05
• Study First Submitted: 2010-05-10
• Study First Submitted QC: 2010-05-10
• Last Update Submitted: 2010-05-10
• Study First Posted: 2010-05-12
• Last Update Posted: 2010-05-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• neuropathic pain

• informed signed consent

Exclusion Criteria

• magnesium intake contra-indication
• severe renal insufficiency
• quinidine intake
• concomitant treatment change 2weeks before inclusion
• evolutive pathology

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain scores (neuropathic pain evaluation questionnaire)	Visit D0

Secondary Outcome Measures

Name	Time	Method
- Numeric scale - quality o f life questionnaires	Visit Week 5

Trial Locations

Locations (1)

CHU Clermont-Ferrand; 🇫🇷 Clermont-Ferrand, France